Tumor volume as a prognostic factor in patients (pts) with locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with induction chemotherapy (IC)

Autor: Alexandre Arthur Jacinto, Augusto Elias Mamere, Marcos Duarte de Mattos, Luciano de Souza Viana, Ana Carolina Lima Chaves Veneziani, Renato de Castro Capuzzo, D.M.F. Palhares, Fernando Coutinho Batista, Carlos Roberto dos Santos, André Lopes Carvalho
Rok vydání: 2017
Předmět:
Zdroj: Journal of Clinical Oncology. 35:e17507-e17507
ISSN: 1527-7755
0732-183X
Popis: e17507 Background: Tumor volume and the ratio of volumetric change have been demonstrated to have a prognostic role in head and neck cancers during definitive treatment in LAHNSCC. The aim of this study was to evaluate the prognostic value of tumor volume assessment during IC. Methods: We retrospectively assessed the tumor volume of 58 pts with LAHNSCC included in a prospective phase II trial which evaluated the safety of a non–5-fluorouracil-based IC (paclitaxel; cisplatin) followed by chemoradiotherapy (cisplatin; 70Gy/35fx) during 2009-2012. The volume of primary tumor (PrimV), all suspicious lymph nodes (LNV) and their sum (SumV) were determined on tomography before (CT1) and after (CT2) IC using a radiotherapy treatment planning system and the ratio of volumetric change was calculated for each variable (PrimV%, LNV% and SumV%). Results: The median follow-up time, the progression free survival (PFS) and the overall survival (OS) was 78,1, 19,3 and 22,5 months, respectively. Fifty-four pts were men, mean age 55,3±8,3y. Most had oropharynx (53%) and stage IV (72%) cancer. The median volume (cm3) was PrimV1= 25,5, LNV1= 7,5, SumV1= 40,7, PrimV2= 10,9, LNV2= 3,0, SumV2= 18,8 and median ratio of change (%) was PrimV% = 55, LNV% = 51 and SumV% = 54. Volume wa s associated with resectability (PrimV1, AUC ROC curve = 0,66, p = 0,04; LNV1, AUC = 0,85, p < 0,001; SumV1, AUC = 0,86, p < 0,001). Pts with SumV% reduction > 35% had better PFS (median 84,0 vs 10,1 months, 3y 52% vs 29%; HR = 0,39, p = 0,01) and OS (median 45,5 vs 17,0 months, 48% vs 21%; HR = 0,49, p = 0,04). On univariate analysis the PFS was correlated with T (p = 0,004), N (p = 0,01), stage (p = 0,03), primary site (p = 0,01), resectability (HR = 0,32, p = 0,001), PrimV1 (p = 0,002), SumV1 (p = 0,001), PrimV2 (p = 0,02), LNV2 (p = 0,04), SumV2 (p = 0,004), PrimV% (p = 0,04), LNV% (p = 0,003) and SumV% (p = 0,04) and OS was associated with T (p = 0,04), N (p = 0,02), stage (p = 0,04), primary site (p = 0,01), resectability (HR = 0,29, p < 0,001) PrimV1 (p = 0,003), LNV1 (p = 0,002) and SumV1 (p < 0,001). Conclusions: Tumor volume and the volumetric response during IC were associated with prognosis in LAHNSCC in the present study. Clinical trial information: NCT00959387.
Databáze: OpenAIRE
Externí odkaz: